|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Total Intangible Assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Management and directors' fees payable | ||||||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Current portion of finance lease liabilities | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Current portion of grant repayable | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Current portion of convertible note payable, net | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-term debt, net of current portion | ||||||||||||||||||||
| Deferred revenue, net of current portion | ||||||||||||||||||||
| Finance lease liabilities, net of current portion | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Grant repayable, net of current portion | ||||||||||||||||||||
| Convertible note payable, net of current portion | ||||||||||||||||||||
| Total Long-Term Liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Deficit | ||||||||||||||||||||
| Common Stock Authorized: 325,000,000 shares of common stock, at $0.001 par value per share Issued and outstanding: 12,044,339 shares and 6,288,988 shares, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total VolitionRx limited Stockholders' Deficit | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total Stockholders' Deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders' Deficit | ||||||||||||||||||||
Loading...
